When the UK government launched its Life Sciences Sector Plan in July 2025, the ambition was clear: combine entrepreneurial freedom with targeted support to secure Britain's place as a leader in one of the highest-value sectors of the modern economy. One year on, the results speak in hard figures. More than £3 billion in new public-private investment has flowed into the sector, validating an approach that prizes private initiative alongside strategic public policy.
The investments announced on 9 July 2026 paint a picture of focused ambition rather than scattergun spending. AstraZeneca is committing £300 million to advance AI-driven drug discovery at its Cambridge headquarters and Macclesfield facility. Moderna has pledged £1 billion over ten years for UK research and development, opening a new innovation centre in Harwell. UCB is investing £500 million in a dedicated R&D hub in Windlesham, Surrey, aimed at transformative medicines for immunological diseases. These are not abstract pledges. They translate into laboratories, equipment, skilled roles and, ultimately, new therapies.
Life sciences are at the heart of this government’s modern Industrial Strategy. We are determined to make the UK a global life sciences superpower, and this investment will create high-skilled jobs, drive innovation and deliver breakthroughs that save lives.
Business Secretary Peter Kyle's words frame the announcement with precision. The Life Sciences Innovative Manufacturing Fund alone has crowded in more than £700 million and created or safeguarded over 1,300 jobs in the past 12 months. A new Jobs Plan targets 66,000 additional roles in priority occupations by 2035 through apprenticeships, technical education and industry-led skills development. Nearly half the sector's existing 360,000 jobs already sit outside London and the south-east, underscoring its contribution to regional economic strength.
Reforms deliver measurable speed
Parallel changes in regulation and approval processes have produced tangible improvements. The average time to set up a commercial clinical trial has fallen from 169 days to 122 days. In April 2026 the 150-day target was met. Under the new joint MHRA-NICE approval process patients are expected to access new medicines up to six months sooner. In June 2026 the NHS in England and Wales approved the world's first immunotherapy for type 1 diabetes, a direct result of accelerated pathways.
Pascal Soriot, chief executive of AstraZeneca, highlighted the practical steps taken. "2026 has been an important year of tangible action advancing UK life sciences. The first ever increase of the NICE threshold since 1999, the establishment of the Health Data Research Service, and measures to speed up clinical trial delivery. We look forward to working with the government to further strengthen its global competitiveness and build on this momentum."
The formal incorporation of the Health Data Research Service as a company on 9 July 2026 adds another pillar. Backed by up to £600 million from government and the Wellcome Trust, it will create a secure, AI-ready health data platform. The government has committed over £2 billion in public funding across the lifetime of the Spending Review to underpin the wider plan.
